# A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

Source: https://onco.cc/trials/nct07140393/  
OnCo record `nct07140393` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Capecitabine, Trastuzumab, Pertuzumab and Trastuzumab rezetecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor is a phase 1/2 interventional study registered as NCT07140393 by Jiangsu HengRui Medicine Co., Ltd., with 120 participants planned, started 2025-10-28 and due to reach its primary completion in 2027-10. Interventions recorded: HRS-4508+ Capecitabine, HRS-4508+ Trastuzumab, HRS-4508+ Trastuzumab+ Pertuzumab, HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel, HRS-4508+ Trastuzumab + Nab-paclitaxel and HRS-4508+ Trastuzumab+ Capecitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07140393
- Phase: 1/2
- Setting: An Open, Multicenter Phase IB/II Clinical Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07140393: https://clinicaltrials.gov/study/NCT07140393

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07140393.json